Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) PT at $32.67

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $32.6667.

Several research firms have weighed in on MAZE. Guggenheim raised their target price on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a report on Monday, September 15th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Maze Therapeutics in a report on Thursday, September 18th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Wedbush started coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 price target for the company. Finally, BTIG Research lifted their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, September 12th.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $27.00 on Friday. The firm has a 50-day moving average price of $17.06 and a two-hundred day moving average price of $13.16. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $28.37.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Insider Activity at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its position in shares of Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock worth $57,000 after acquiring an additional 3,774 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after acquiring an additional 438,274 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Maze Therapeutics during the second quarter valued at approximately $125,000. Bank of America Corp DE lifted its position in Maze Therapeutics by 33.6% during the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after buying an additional 1,455 shares in the last quarter. Finally, CW Advisors LLC acquired a new position in Maze Therapeutics during the second quarter valued at approximately $371,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.